Clinical trial · no report yet · Phase 1
GEN602
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
- NCT03775525 ↗
- Unknown
- Genzada Pharmaceuticals USA, Inc.
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma
- Phase
- Phase 1
- Status
- Unknown
- Conditions
- Advanced Cancer; Gastric Cancer; Breast Cancer; Pancreatic Cancer; Prostate Cancer Metastatic; Colo-rectal Cancer; Solid Tumor; Solid Carcinoma; Solid Carcinoma of Stomach; Cancer of Stomach; Lymphoma; Sarcoma; Cutaneous T Cell Lymphoma; Head and Neck Squamous Cell Carcinoma; Basal Cell Carcinoma; Cutaneous T-cell Lymphoma; Cutaneous Squamous Cell Carcinoma
- Interventions
- GZ17-6.02; Capecitabine
- Arms
- Experimental: monotherapy · Experimental
- Experimental: Combination with Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer · Experimental
- Experimental: Combination with Capecitabine in Metastatic Colorectal Cancer · Experimental
- Enrollment
- 127 (estimated)
- Primary outcomes
- maximum tolerated dose (MTD)
- Recommended dose of GZ17-6.02 for future phase II clinical studies
- Dose-limiting toxicity
- Sponsor
- Genzada Pharmaceuticals USA, Inc. with Translational Drug Development
- Start
- Mar 1, 2019
- Primary completion
- May 2023 (estimated)
- Results posted
- No
- Registry record
- NCT03775525 · updated Dec 23, 2022
Publications
linked from the registry- Booth L, Roberts JL, Spasojevic I, Baker KC, Poklepovic A, West C, Kirkwood JM, Dent P. GZ17-6.02 kills PDX isolates of uveal melanoma. Oncotarget. 2024 May 17;15:328-344. doi: 10.18632/oncotarget.28586. PubMed 38758815
- Booth L, West C, Von Hoff D, Dent P. Mechanisms of GZ17-6.02 resistance. Anticancer Drugs. 2022 Jun 1;33(5):415-423. doi: 10.1097/CAD.0000000000001203. PubMed 35276694